pt141 capsule PT-141 (Bremelanotide) PT-141 Bremelanotide - Injections
Description
PubMed Central PMCID: PMC4991244
Dysregulation of TDP-43 induces its cytoplasmic accumulation and aggregation, which is a hallmark of ALS (96)
Injectable peptide formulations often include antioxidants to combat oxidative degradation, but these protective agents have limited capacity
doi:10.1056/NEJMoa2309000
